Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2005

View Archived Issues

TPA blocks growth of pancreatic tumors in mice

In vitro activity of AMN-107 against imatinib-resistant CML cell lines

2-Methoxyestradiol shows promise in the management of rheumatoid arthritis

Epicatechin gallate maintains mitochondrial activity during wound healing

Antileukinate protects mice against cerulein-induced acute pancreatitis

Preclinical studies of oglemilast uncover its antiarthritic potential

Pharming's recombinant human fibrinogen selected for U.S. Army project

AD-452 enters phase IIb study in rheumatoid arthritis

TAP terminates license of Flamel technology for delivery of lansoprazole

Enrollment completed in phase III efficacy study of frovatriptan

Antisoma reopens phase I study of AS-1411 to renal and lung cancer patients

Solvay launches Duodopa in 12 new European countries

Recent patents report novel agents for thrombotic disorders

Cephalon files NDA for OraVescent fentanyl for breakthrough cancer pain

Memantine for cocaine and tobacco addiction

Ambien CR receives FDA approval for the treatment of insomnia

Labopharm receives European approvals for once-daily tramadol

Recent Allergan patent reports new treatments for glaucoma

Patient recruitment for phase I evaluation of N-acetylcysteine in cocaine dependence

New agents for asthma patented

Proquad approved to protect children from measles, mumps, rubella & varicella

ICC-1132 induces immune responses against P. falciparum in healthy volunteers

New clinical data on ziconotide for the treatment of chronic pain

Olanzapine reduces nausea and vomiting in patients receiving emetogenic chemotherapy

New data on the efficacy of aprepitant in the prevention of CINV

Update on the potential of SVT-40776 as a novel treatment for overactive bladder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...